rossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company's T-BoltTM therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow's efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
03/18/26	$77,000,000	Series B	Arkin Bio Ventures Blood Cancer United Therapy Acceleration Program BVF Partners Eli Lilly and Company Hamilton Square Partners Management Libbs Ventures Liberty Global Ventures LifeLink Ventures Mirae Asset Venture Investment MPM BioImpact Pfizer Venture Investments Polaris Partners Sixty Degree Capital Taiho Ventures	undisclosed